Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment.

Pharmacology - 1 Jan 2014

Günaldı Meral, Erkisi Melek, Afşar Ciğdem Usul, Erçolak Vehbi, Paydas Semra, Kara I Oguz, Sahin Berksoy, Gulec Umran Kucukgoz, Secilmis Ata

Abstract excerpt

BACKGROUND: Several previous studies have examined the effect of CYP2D6 gene polymorphism on the efficacy and metabolism of tamoxifen (Tamoxifen Teva, Nolvadex) in the treatment of breast cancer. In the present study, the metabolic profiles associated with various CYP2D6 genotypes were evaluated. METHOD: In the present study 92 Turkish breast cancer patients with early-stage hormone receptor-positive tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Bone Density

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Endometrium

Share to Hyperplasia

Share to Tamoxifen

Share to Turkey

Share to Ultrasonography

Source

Identifiers

PMID: 25378122
DOI: 10.1159/000363304

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment.PMID 25378122Read ↗

Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.Semantic proximity Read ↗

Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read ↗

Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.Semantic proximity Read ↗

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.Semantic proximity Read ↗

CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical RelevanceSemantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.